TY - JOUR T1 - SARS-CoV-2 seroprevalence and detection fraction in Utah urban populations from a probability-based sample JF - medRxiv DO - 10.1101/2020.10.26.20219907 SP - 2020.10.26.20219907 AU - Matthew H. Samore AU - Adam Looney AU - Brian Orleans AU - Tom Greene AU - Nathan Seegert AU - Julio C Delgado AU - Angela Presson AU - Chong Zhang AU - Jian Ying AU - Yue Zhang AU - Jincheng Shen AU - Patricia Slev AU - Maclean Gaulin AU - Mu-Jeung Yang AU - Andrew T. Pavia AU - Stephen C. Alder Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/27/2020.10.26.20219907.abstract N2 - This project’s aim was to generate an unbiased estimate of the incidence of SARS-CoV-2 infection in four urban counties in Utah. A multi-stage sampling design was employed to randomly select community-representative participants 12 years and over. Between May 4 and June 30, 2020, surveys were completed and sera drawn from 8,108 individuals belonging to 5,125 households. A qualitative chemiluminescent microparticle immunoassay was used to detect the presence of IgG antibody to SARS-CoV-2. The overall prevalence of IgG antibody to SARS-CoV-2 was estimated at 0.8%. The estimated seroprevalence-to-case count ratio was 2.4, corresponding to a detection fraction of 42%. Only 0.2% of individuals who had a nasopharyngeal swab collected were reverse transcription polymerase chain reaction (RT-PCR) positive. The prevalence of antibodies to SARS-CoV-2 in Utah urban areas between May and June was low and the prevalence of positive RT-PCR even lower. The detection fraction for COVID-19 in Utah was comparatively high.Article Summary Probability-based sampling provides an effective method for robust estimates of community-based SARS-CoV-2 seroprevalence and detection fraction among urban populations in Utah.Competing Interest StatementAll authors report funding from Utah State Government. Dr. Slev reports other from EUROIMMUN, outside the submitted work Dr. Pavia reports Royalties as co-editor of Sanford Guide from Antimicrobial Therapy Inc, and Honoraria for preparing CME materials for WebMDClinical TrialThis was not a clinical trial; rather, the design was observational, non-interventionalFunding StatementThis work was funded by the State of Utah.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This surveillance project was designated by the University of Utah Institutional Review Board as non-research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual level data will not be publicly available but aggregated data will be. ER -